Nebenwirkungen · Temozolomide Accord
Temozolomide Accord 5 mg hard capsules. Temozolomide Accord 20 mg hard capsules. Temozolomide Accord 100 mg hard capsules. Temozolomide Accord 140 mg hard capsules. Temozolomide Accord 180 mg hard capsules. Temozolomide Accord 250 mg hard capsules. · Abschnitt 4.8 · PDF-Seite 12
HOS-212033 · Präparat HOS-154808
Myelosuppression (neutropenia and thrombocytopenia), which is known dose-limiting toxicity for most cytotoxic agents, including TMZ, was observed. When laboratory abnormalities and adverse events were combined across concomitant and monotherapy treatment phases, Grade 3 or Grade 4 neutrophil abnormalities including neutropenic events were observed in 8% of the patients. Grade 3 or Grade 4 thrombocyte abnormalities, including thrombocytopenic events were observed in 14% of the patients who received TMZ.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-06-02T11:26:00Z · SHA-256 d5a737eecba60b68093f4466fc687af593eae980cbf153f31b54b82f3b09990b · Passage 7d2e672590c160f16c8fcf2222c15076d32553886e01582be94a93212a512748 · Zeichen 9360–9867 im Abschnitt